December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

30.95 -0.26 (-0.83%)
Official Closing Price Updated: 7:00 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries Limited American Depositary Shares

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
31 32 Next >
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Ethereum Price Predictions: Where Will the ETH Crypto Go After Retaking $3,000? ↗
Ethereum price predictions are a hot topic on Monday as crypto traders wonder where the token will go after surpassing $3,000. 
Via InvestorPlace
News headline image
Jefferies Just Raised Its Price Target on Salesforce (CRM) Stock ↗
Salesforce stock is rising higher on Monday after CRM shares got an increased price target from Jefferies analysts this morning. 
Via InvestorPlace
News headline image
TEVA Stock Pops 4% as Teva Receives FDA Approval ↗
Teva Pharmaceutical stock is rising higher on Monday after partner company Alvotech got approval from the FDA for a Humira biosimilar. 
Via InvestorPlace
News headline image
Why Is Generic Drugs Player Teva Pharma Stock Trading Higher Today? ↗
FDA-approved Simlandi (adalimumab-ryvk): a high-concentration biosimilar to Humira for rheumatoid arthritis, psoriasis, and more. 
Via Benzinga
News headline image
Beyond The Numbers: 8 Analysts Discuss Teva Pharmaceutical Indus Stock ↗
 
Via Benzinga
News headline image
A Preview Of Teva Pharmaceutical Indus's Earnings ↗
 
Via Benzinga
News headline image
Li Auto Posts Q4 Earnings, Joins Teva Pharmaceutical And Other Big Stocks Moving Higher In Monday's Pre-Market Session ↗
U.S. stock futures were lower this morning, with the Dow futures trading lower by over 50 points on Monday. 
Via Benzinga
Topics Stocks
News headline image
Teva and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO® in China
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
6 reasons to buy Teva Pharmaceuticals stock sooner than later
Investors seeking a long-term and undervalued pharmaceutical play should take a close look at Teva Pharmaceuticals, and here are six reasons why 
Via MarketBeat
Topics Lawsuit
News headline image
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
From Alvotech
Via GlobeNewswire
News headline image
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential ↗
MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months. 
Via Talk Markets
News headline image
Teva Pharma CEO Dismisses Split Speculations Expects Significant Interest For Its API Business Divestiture: Report ↗
Teva Pharmaceutical Industries confirms unity and dispels split rumors. CEO Richard Francis emphasizes the synergy between generics and branded drugs. 
Via Benzinga
News headline image
Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘574) Antibody at the 2024 ECCO Annual Meeting
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Why This Teva Pharmaceutical Analyst Is Turning Bullish On The Austedo Franchise ↗
Shares of Teva Pharmaceutical Industries Ltd (NYSE: TEVA) climbed in early trading on Monday, after several analysts raised their forecasts. 
Via Benzinga
News headline image
CymaBay Therapeutics, ContextLogic, Snap And Other Big Stocks Moving Higher On Monday ↗
U.S. stocks were mixed, with the Nasdaq Composite trading almost flat on Monday. Shares of CymaBay Therapeutics, Inc. (NASDAQ: CBAY) rose sharply in today’s pre-market trading. 
Via Benzinga
Topics Stocks
News headline image
Teva Pharmaceutical To Rally Around 58%? Here Are 10 Top Analyst Forecasts For Monday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
News headline image
3 Biotech Stocks to Buy for the Next Bull Run: February 2024 ↗
These are the biotech stocks to buy that you must have on your watchlist for the coming bull run. It could get started as soon as this month. 
Via InvestorPlace
News headline image
Teva Pharmaceutical Industries (TEVA) Q4 2023 Earnings Call Transcript ↗
TEVA earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
News headline image
Boeing Posts Upbeat Results, Joins Stryker, Automatic Data Processing And Other Big Stocks Moving Higher On Wednesday ↗
U.S. stocks traded mostly lower, with the Nasdaq Composite falling over 200 points on Wednesday. 
Via Benzinga
Topics Stocks
News headline image
Generic Drug Player Teva Pharma To Divest Its Active Pharmaceutical Ingredient Business, Q4 Earnings Surpass Estimates ↗
Teva Pharmaceutical surpasses Q4 2023 sales expectations, reporting $4.46 billion. Teva plans to divest API business for revenue optimization. Outlook for FY 2024. 
Via Benzinga
News headline image
Teva Sinks On Lackluster Profit Outlook Despite Walloping Quarterly Projections ↗
Teva Pharmaceutical easily beat fourth-quarter views, but its 2024 profit guidance left something to be desired. 
Via Investor's Business Daily
News headline image
Nasdaq Futures Plummet As Alphabet, AMD Disappointments Sour Sentiment; Spotlight Shifts To Fed Statement, Powell's Presser ↗
The record run of the market faces risk as the big tech earnings season got off to a negative start, casting cloud on profit outlook. 
Via Benzinga
Topics Economy
News headline image
Teva Reports Growth in Fourth Quarter and Full Year 2023
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva Announces Intention to Divest API Business as Part of Pivot to Growth Strategy
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Stocks Mixed Ahead Of Big Tech Earnings ↗
Stocks are a mixed bag this afternoon, following the start of the Federal Reserve's two-day policy meeting. 
Via Talk Markets
Topics Economy
News headline image
Enphase Energy To Rally Over 35%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
News headline image
Earnings Scheduled For January 31, 2024 ↗
Companies Reporting Before The Bell • Novartis (NYSE:NVS) is likely to report quarterly earnings at $1.68 per share on revenue of $11.56 billion. 
Via Benzinga
News headline image
Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism? ↗
An analyst sees the Satya Nadella-led company's earnings to be the key barometer for AI spending. 
Via Benzinga
Topics Artificial Intelligence
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
31 32 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.